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OBJECTIVE—Fibroblast growth factor-21 (FGF-21) is a potent
metabolic regulator, which in animal models has been shown to
improve glucose metabolism and insulin sensitivity. Recently,
FGF-21 was shown to be expressed and secreted from murine
muscle cells in response to insulin stimulation.
RESEARCH DESIGN AND METHODS—We studied muscular
FGF-21 expression and plasma FGF-21 after acute insulin stim-
ulation in young healthy men during a hyperinsulinemic-
euglycemic clamp. Furthermore, we investigated systemic levels
and muscle FGF-21 expression in humans with or without insulin
resistance and chronic elevated insulin.
RESULTS—FGF-21 was barely detectable in young healthy men
before insulin infusion. After 3 or4ho finsulin infusion during a
hyperinsulinemic-euglycemic clamp, muscular FGF-21 expres-
sion increased signiﬁcantly. Plasma FGF-21 followed the same
pattern. In individuals with chronic elevated insulin, muscular
FGF-21 expression was associated with hyperinsulinemia in men
but not in women. In plasma, hyperinsulinemia and fasting
glucose were positively associated with plasma FGF-21 while
plasma FGF-21 correlated negatively with HDL cholesterol. No
associations between muscle and plasma FGF-21 were found in
the individuals with chronic hyperinsulinemia.
CONCLUSIONS—FGF-21 is expressed in human skeletal mus-
cle in response to insulin stimulation, suggesting that FGF-21 is
an insulin-regulated myokine. In support, we found an associa-
tion between chronic hyperinsulinemia and levels of FGF-21.
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ibroblast growth factor-21 (FGF-21), which is a
member of the FGF super family, has recently
been described as playing important roles in
controlling glucose and lipid metabolism (1,2).
Therapeutic administration of FGF-21 in rodents and
nonhuman primates exerts metabolic control by protect-
ing the animals from diet-induced obesity and lowering
fasting plasma glucose, triglycerides, and insulin and glu-
cagon levels in diabetic animal models (3–5). FGF-21 also
improves the lipoprotein proﬁles by decreasing LDL and
total cholesterol and increasing HDL cholesterol (4).
FGF-21 transgenic mice exhibit similar metabolic charac-
teristics, namely reduced adiposity and resistance to diet-
induced metabolic disturbances (3).
Mechanistic animal studies focusing on the role of
FGF-21 during fasting conditions have shown that FGF-21
is a downstream mediator of peroxisome proliferator–
activated receptor- (PPAR-) (6,7), and PPAR-–induced
FGF-21 release leads to 1) stimulation of lipolysis in
adipose tissue for the release of fatty acids, 2) direct
stimulation of hepatic ketogenesis, and 3) induction of
torpor in rodents.
In contrast to the animal studies, little information is
available on the functional role of FGF-21 in humans. In
healthy humans there is a large interindividual variation in
serum FGF-21 with no correlation to age, sex, BMI, or
plasma glucose (8). Two cross-sectional studies on Chi-
nese individuals showed that plasma FGF-21 is elevated in
both lean individuals diagnosed with type 2 diabetes (9)
and in obese subjects (10) compared with healthy control
subjects; accordingly, circulating FGF-21 was shown to be
positively correlated with fasting insulin. Recently, two
contradicting studies showed that plasma FGF-21 either
increased during a hyperinsulinemic-euglycemic clamp
(11) or showed no correlations to parameters of the
hyperinsulinemic-euglycemic clamp (12).
Muscle tissue has received attention for being an impor-
tant secretory organ able to secrete metabolic regulatory
proteins (myokines). The main example is interleukin-6,
which is released systemically in response to exercise and
modulates metabolic functions in adipose tissue (13).
Recently it was shown that FGF-21 is expressed and
released from muscle tissue in Akt-overexpressing mice
(14). Murine muscle cell culture studies supported these
ﬁndings showing FGF-21 release in response to insulin
stimulation and activated Akt.
Thus, we hypothesize that FGF-21 is expressed and
secreted from muscle tissue in humans in response to
insulin. We investigated 1) FGF-21 expression in plasma
and muscle from 23 healthy subjects during a
hyperinsulinemic-euglycemic clamp and 2) FGF-21 ex-
pression in muscle and plasma from 198 individuals with
or without insulin resistance.
RESEARCH DESIGN AND METHODS
Protocol for clinical studies. We studied FGF-21 expression and plasma
levels in 1) healthy young males during a hyperinsulinemic-euglycemic clamp
and 2) individuals with or without type 2 diabetes. All studies were approved
by the Ethics Committee of Copenhagen and Frederiksberg Council, Den-
mark. All participants were given both oral and written information about the
experimental procedures before giving their written informed consent. Before
the experiment day, all subjects underwent a thorough clinical examination
and blood samples for evaluation of renal, hepatic, and thyroid function;
hemoglobin; white blood cell counts; thrombocytes; electrolytes; plasma
coagulation factors; and plasma glucose were collected.
Human study 1. Fifteen subjects received a 3-h hyperinsulinemic-
euglycemic clamp with blood sampling and muscle biopsies before and after
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diabetes.diabetesjournals.org DIABETES, VOL. 58, DECEMBER 2009 2797the clamp, while additionally eight subjects underwent a 6-h clamp with
muscle biopsies taken at 0, 2, 4, and 6 h during the clamp, as previously
published (15). All subjects had peripheral catheters placed in an antecubital
vein for infusion of insulin, glucose, and potassium and one catheter in a
contralateral hand vein for blood sampling. Insulin (Actrapid, Novo Nordisk;
100 units/ml) was infused continuously at an infusion rate of 0.08 units/min
per m
2. Glucose (200 g/1,000 ml) was infused at rates adjusted to maintain
blood glucose at 5 mmol/l. To maintain potassium at normal values, isotonic
saline with potassium was infused if needed. Arterialized blood was analyzed
at intervals of 10 min for glucose and potassium concentrations.
Human study 2. Individuals with type 2 diabetes were recruited, and healthy
control subjects were matched by BMI. The group has previously been
described in the study by Nielsen et al. (16). Using a cross-sectional case-
control design, participants (n  198) were divided into three distinct groups
according to the result of an oral glucose tolerance test (normal glucose
tolerance [NGT], impaired glucose tolerance [IGT], or type 2 diabetes).
Exclusion criteria were treatment with insulin, recent or ongoing infection,
history of malignant disease, or treatment with anti-inﬂammatory drugs. Data
from 198 subjects were complete, and only those subjects were included in the
ongoing analysis.
Participants reported in the laboratory between 8:00 and 10:00 A.M. after an
overnight fast. Blood samples were drawn from the antecubital vein, and a
muscle biopsy was obtained. In addition, an oral glucose tolerance test was
performed.
Plasma ELISA analysis. Plasma concentrations of FGF-21 were measured
using a commercial ELISA kit (Human FGF-21; Biovendor, Germany). Plasma
samples were diluted 1:1 and analyzed according to the manufacturer’s
instructions. All samples were run as duplicates and were within the range of
the standard curve. The results were in the lower range of the standard curve;
therefore, a coefﬁcient of variation within the duplicates of 30% was accepted.
The interassay coefﬁcients of variation were validated within our work and
were 27%.
RNA extraction and quantitative PCR analysis. RNA was extracted from
20–30 mg of skeletal muscle biopsies using TriZol (Invitrogen, Carlsbad, CA)
and reverse transcribed using random hexamer primers (TaqMan reverse
transcription reagents; Applied Biosystems). Real-time PCR was performed on
an ABI PRISM 7900 Sequence Detection System (PE Biosystems) using
TaqMan reagents (Applied Biosystems). Sequence-speciﬁc FGF-21 primer/
probe sets were used for FGF-21 ampliﬁcation, while predeveloped household
TaqMan primer/probe sets (Applied Biosystems) were used for 18s and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) detection. The relative
expression of FGF-21 was normalized to the endogenous control and ex-
pressed as FGF-21 expression per 18s or GAPDH expression. The levels of 18s
or GAPDH mRNA in the skeletal muscle were not inﬂuenced by the treatment
(data not shown).
Statistics. All statistical analyses were conducted using SPSS for Windows,
release 15.0 (SPSS, Chicago, IL). The assumption of normality was tested
using a Kolmogorov-Smirnov test. If data did not reach normality, a logarith-
mic transformation was performed. P  0.05 was considered as signiﬁcant. In
the experimental clamp study, the differences between prevalues and 3-h
values in plasma and muscle FGF-21 were analyzed using paired t test. In the
epidemiological study, unless otherwise stated, analyses were performed with
sexes separated. Differences between different groups were tested by ANOVA.
If ANOVA revealed signiﬁcant differences between the glycemic groups, a
Tukey post hoc test was added. The association of plasma or muscle FGF-21
and variables related to metabolic syndrome was tested using linear regres-
sion analysis. Plasma or muscle FGF-21 was set as the dependent variable and
variables related to metabolic syndrome as independent variables with
adjustments for age and BMI.
RESULTS
The effect of acute hyperinsulinemia on muscle
FGF-21 mRNA and plasma FGF-2. Muscle biopsies
were obtained before and during hyperinsulinemic-
euglycemic clamp from healthy young men (Fig. 1A).
Before insulin infusion, FGF-21 was expressed at very low
levels. After 3–4 h of insulin infusion, muscular FGF-21
mRNA increased signiﬁcantly (P  0.001) and was detect-
able in 21 of 23 subjects. Plasma FGF-21 followed the same
pattern (Fig. 1B). Before insulin infusion, plasma FGF-21
could only be detected in 4 of 14 subjects. After the3ho f
insulin infusion, FGF-21 was detectable in 11 of 14 sub-
jects with general increases in all subjects (P  0.006).
Muscle FGF-21 and plasma FGF-21 during chronic
hyperinsulinemia. Muscle biopsies were obtained from
individuals with either NGT, IGT, or type 2 diabetes, and
groups were matched for BMI. The characteristics of the
groups are presented in Table 1. Dividing the subjects into
quartiles according to fasting insulin levels showed that the
25% with the highest fasting insulin levels had signiﬁcantly
higher FGF-21 expression than the lowest 25% (Fig. 2). This
association was only present in men, not women. Because
an association between age and muscle FGF-21 was
demonstrated (P  0.001), further adjustments for age and
BMI were performed in a multivariate regression analysis.
We found a positive association with fasting insulin and
homeostasis model assessment (HOMA) score (Table 2).
Moreover, muscle FGF-21 mRNA was negatively associ-
ated with HDL cholesterol (data not shown). In general,
plasma FGF-21 followed the same pattern as that found for
muscle FGF-21 mRNA (Table 2). A positive relationship
was demonstrated between plasma FGF-21 and fasting
plasma insulin (0.172, R
2  0.022, and P  0.04),
although the association did not remain signiﬁcant when
individuals were divided according to sex. Plasma FGF-21
was positively correlated with fasting glucose, HOMA, and
triglycerides in men and negatively correlated with HDL
cholesterol in women when analyzed separately (Table 2).
Furthermore, plasma FGF-21 was signiﬁcantly increased
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FIG. 1. Muscle and plasma FGF-21 during acute hyperinsulinemia.
Healthy young men underwent a hyperinsulinemic-euglycemic insulin
clamp. Fifteen subjects had muscle biopsies and blood samples before
and after 3 h, while additionally eight subjects had muscle biopsies
before and 2 and 4 h into the clamp. Data are presented as FGF-21
expression normalized to 18s expression. A: Muscle FGF-21 expression
was signiﬁcantly increased by 3–4 h (P  0.001, paired t test). B:
Plasma FGF-21 increased signiﬁcantly after3h( P  0.006, paired t
test).
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146.2  2.5 pg/ml versus 102.2  2.6 pg/ml (P  0.008). No
associations between muscle and plasma FGF-21 were
found.
DISCUSSION
The present study shows that insulin stimulates the ex-
pression of FGF-21 in human skeletal muscle and induces
an increase in circulating FGF-21 levels. In addition to the
acute effect of insulin on muscular FGF-21 expression, we
found a positive correlation between fasting insulin and
muscle FGF-21 mRNA and plasma FGF-21 in individuals
with a wide range of insulin sensitivity. This was particu-
larly reﬂected in the acute in vivo insulin infusion study
where unstimulated young muscles in most cases did not
express FGF-21 at detectable levels. Moreover, we found a
correlational relationship between muscle FGF-21 expres-
sion and age. In line with previous studies (9,10), we did
not ﬁnd associations between plasma FGF-21 and age.
The ﬁnding that muscular FGF-21 expression is regu-
lated by insulin is in accordance with a recent report from
Izumiya et al. (14), which found that insulin induced
FGF-21 expression in murine muscle cells. In the latter
study, FGF-21 was identiﬁed via microarray screening for
genes that were upregulated in Akt-overexpressing mice.
Thus, the pathway for regulation for FGF-21 in muscle
seems completely different from regulation of FGF-21
expression in liver, where FGF-21 is highly expressed.
Several animal studies have focused on the regulation of
FGF-21 in liver (6,7,17). Here FGF-21 is controlled by
TABLE 1
Characteristic of subjects with NGT, IGT, and type 2 diabetes
Men Women
Mean
95% CI
P Mean
95% CI
P Low High Low High
Age (years)
NGT 55.7 52.4 59.0 48.7 44.5 52.8
IGT 58.9 51.9 65.9 60.5* 53.2 67.8
T2D 60.7 58.3 63.2 0.06 57.0* 52.4 61.8 0.002
BMI (kg/m
2)
NGT 29.7 28.3 31.1 30.3 26.8 33.7
IGT 33.0 30.5 35.4 31.3 27.1 35.4
T2D 30.4 29.2 31.7 0.06 31.8 28.3 35.3 0.81
Waist circumference (cm)
NGT 106.2 102.7 109.8 95.3 86.7 104.0
IGT 114.7* 109.0 120.4 99.2 92.4 106.0
T2D 108.7 105.5 111.8 0.05 100.2 93.0 107.4 0.64
Waist-to-hip ratio
NGT 0.99 0.97 1.01 0.87 0.82 0.91
IGT 1.02 0.99 1.05 0.86 0.83 0.88
T2D 1.01 1.00 1.03 0.07 0.88 0.85 0.91 0.69
Glucose (mmol/l)†
NGT 5.23 5.11 5.35 5.00 4.85 5.22
IGT 5.83 5.55 6.12 5.97* 5.61 6.35
T2D 9.39*‡ 8.54 10.31 0.001 7.93*‡ 6.60 9.53 0.001
Insulin (pmol/l)†
NGT 46.5 40.4 53.5 39.5 30.1 51.7
IGT 95.8* 73.7 124.5 63.4 48.6 82.9
T2D 71.2* 58.1 87.2 0.001 69.8* 48.8 100.0 0.01
A1C (%)†
NGT 5.51 5.44 5.57 5.57 5.44 5.71
IGT 5.90 5.78 6.02 6.02 5.84 6.20
T2D 7.26*‡ 6.90 7.64 0.001 6.71*‡ 6.20 7.25 0.001
HOMA score†
NGT 0.88 0.76 1.01 0.74 0.57 0.96
IGT 1.83* 1.42 2.37 1.23 1.06 1.62
T2D 1.63* 1.32 2.01 0.001 1.49* 1.03 2.15 0.002
FGF-21, plasma (pg/ml)†
NGT 103.3 79.6 134.2 99.6 78.2 126.9
IGT 143.3 116.9 175.8 151.0 105.2 216.6
T2D 149.0 119.8 185.4 0.07 136.0 98.9 186.9 0.09
FGF-21, mRNA
(expression/GAPDH)†‡§
NGT 1.83 1.28 2.63 2.14 1.23 3.73
IGT 1.83 0.84 3.97 3.68 1.67 8.10
T2D 2.62 1.85 3.71 0.33 4.28 1.07 6.18 0.54
For men, n  59 NGT, 18 IGT, and 65 type 2 diabetic (T2D); for women, n  27 NGT, 12 IGT, and 17 type 2 diabetic. P value is shown for
one-way ANOVA. *Statistical signiﬁcant difference from NGT (P  0.05) after Tukey post hoc test. †Log-transformed before analysis; data
shown as geometric mean. ‡Statistical signiﬁcant difference from IGT (P  0.05) after Tukey post hoc test. §Number of subjects: men is 56
NGT/14 IGT/52 type 2 diabetic and women 24 NGT/11 IGT/13 type 2 diabetic.
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the induction of FGF-21. The liver expression of FGF-21 is
closely associated with fasting/fed transition in mice as
PPAR-, and thus FGF-21, is induced by fasting (18). In the
muscles, however, FGF-21 expression seems to by regu-
lated by the insulin/Akt-signaling pathway.
In studying patients with chronic hyperinsulinemia, we
found correlations between plasma and muscle FGF-21
and fasting insulin. Intriguingly, the association between
muscle FGF-21 and insulin was only present in men.
Human myocardial studies have shown a sex-dependent
regulation of Akt with increased nuclear localization of
phosphor-Akt in young women. This increased activity of
Akt in women might explain the large muscular expression
of FGF-21 in our female subjects with NGT (19). In
addition, estrogen stimulates Akt phosphorylation and
nuclear translocation. The women in our study were not
controlled for estrogen and menstrual-cycle status, which
can explain the large variation in FGF-21 expression that
we ﬁnd in our female subjects and thus the lack of
associations to fasting insulin levels.
We were not able to determine any correlation between
muscle FGF-21 mRNA and plasma FGF-21 even though
both correlated with fasting insulin. This indicates that
muscle tissue is not the primary source of FGF-21 during
chronic hyperinsulinemia. Previous studies have shown
that plasma FGF-21 correlated signiﬁcantly with FGF-21
expression in adipose tissue, suggesting that the adipose
tissue might be the primary source of plasma FGF-21 in
humans (10). Thus, FGF-21 expression in muscles may
have a paracrine role in the muscle tissue.
In conclusion, insulin stimulates muscular expression of
FGF-21 and increases plasma FGF-21. Moreover, muscular
FGF-21 expression is associated with hyperinsulinemia.
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FIG. 2. Muscle FGF-21 expression during chronic hyperinsulinemia.
Men (A) and women (B) were divided into quartiles based on fasting
insulin levels (low  25% lowest, med  middle 50%, high  25%
highest). Data are presented as geometric mean and 95% CI. In men,
the “high” quartile had signiﬁcantly higher FGF-21 expression than the
“low” quartile (P  0.04). No signiﬁcance was found in women. *P <
0.05.
TABLE 2
Linear regression of muscle FGF-21 expression adjusted by GAPDH and plasma FGF-21 for men and women
Muscle FGF-21 mRNA Plasma FGF-21
 Coefﬁcients
95% CI
R
2 P  Coefﬁcients
95% CI
R
2 P Low High Low High
Men (n  122 for muscle and n  142
for plasma)
Body weight (kg) 0.002 0.013 0.017 0.095 0.75 0.001 0.009 0.009 0.021 0.97
Waist-to-hip ratio 0.187 1.916 1.543 0.094 0.83 0.097 1.034 1.228 0.021 0.87
Waist circumference (cm) 0.002 0.023 0.019 0.094 0.85 0.003 0.010 0.016 0.023 0.66
Glucose (mmol/l)* 0.309 0.273 0.891 0.102 0.30 0.446 0.055 0.838 0.056 0.03
Insulin (pmol/l)* 0.465 0.100 0.829 0.140 0.01 0.194 0.048 0.437 0.039 0.12
A1C (%)* 0.428 0.799 1.654 0.097 0.49 0.646 0.134 1.425 0.040 0.10
HOMA score* 0.393 0.058 0.729 0.133 0.02 0.238 0.015 0.461 0.052 0.04
HDL cholesterol* 0.864 1.600 0.128 0.134 0.02 0.496 1.007 0.015 0.047 0.06
FGF-21, plasma (pg/ml)* 0.139 0.102 0.380 0.104 0.26
Women (n  48 for muscle and n  56
for plasma)
Body weight (kg) 0.001 0.024 0.024 0.067 1.00 0.003 0.007 0.013 0.097 0.59
Waist-to-hip ratio 0.568 1.558 2.694 0.073 0.59 0.626 1.542 0.290 0.124 0.18
Waist circumference (cm) 0.010 0.014 0.034 0.082 0.41 0.009 0.019 0.001 0.147 0.07
Glucose (mmol/l)* 0.394 1.019 1.807 0.074 0.58 0.114 0.520 0.749 0.095 0.72
Insulin (pmol/l)* 0.253 0.914 0.408 0.080 0.45 0.010 0.285 0.305 0.092 0.95
A1C (%)* 0.695 2.606 3.996 0.071 0.67 0.321 1.165 1.807 0.096 0.67
HOMA score* 0.199 0.842 0.443 0.076 0.54 0.008 0.278 0.295 0.092 0.96
HDL cholesterol* 0.319 1.045 1.682 0.072 0.64 0.730 1.294 0.166 0.197 0.01
FGF-21, plasma (pg/ml)* 0.534 1.190 0.121 0.112 0.11
Regressions adjusted by BMI and age. *Log-transformed before analysis.
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